ClinicalTrials.gg
Enrolling by invitationNCT05210803Updated Aug 5, 2026

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

A Phase 2 interventional study of Standard of Care and Ranibizumab in Neovascular Age-Related Macular Degeneration (nAMD), sponsored by AbbVie. Enrolling by invitation at 16 sites in United States. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Planned enrollment
43rd of 124
116 · median 64
Started
2021
with 3 others
Phase 2
24 of 125
1 open now
Registered
119th of 125
by date

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 43rd largest by planned enrollment of the 124 interventional ones that give a count, is one of 4 that started in 2021, is one of 24 in phase 2, and was the 119th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of nAMD in which they received suprachoroidal space (SCS) administration of ABBV-RGX-314. Enrollment of each participant in the current study should occur after the participant has completed either the end of study or early discontinuation visit in the previous (parent) clinical study. Participants will be followed for up to 5 years after ABBV-RGX-314 administration (inclusive of the parent study). As such, the total study duration for each participant may vary depending on when they enroll in the current study following ABBV-RGX-314 administration in the parent study.

03

Conditions studied

  • Neovascular Age-Related Macular Degeneration (nAMD)

Keywords

  • Gene Therapy
  • AMD
  • wet AMD
  • wAMD
  • nAMD
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must provide written, signed for this study.
  2. Must have been enrolled in a previous clinical study of ABBV-RGX-314 in the treatment of nAMD and must have received an SCS injection of ABBV-RGX-314 in that study.
  3. Must be willing and able to comply with all study procedures.

Exclusion criteria

Exclusion Criteria:

1. None

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Other
    Standard of Care

    Dose Level (DL) 1-3 participants who received ABBV-RGX- 314 in the parent study will continue to receive standard of care for the study duration.

    Drug: Standard of Care

  • Other
    Supplemental Treatment

    DL 4 participants from the parent study will be able to receive supplement ranibizumab based on protocol-specified criteria if they develop worsening nAMD activity.

    Drug: Standard of Care · Drug: Ranibizumab

Interventions

  • DrugStandard of Care

    Standard of Care

  • Injection

    Also known as: LUCENTIS

06

What researchers measure

Primary outcomes

  1. Incidences of ocular Adverse Events and any Serious Adverse Events

    To evaluate the long-term safety of ABBV-RGX-314

    Time frame: 5 years inclusive of parent study

Secondary outcomes

  1. Incidences of non-ocular Adverse Events and any Adverse Events of Special Interest

    To evaluate the long-term safety of ABBV-RGX-314

    Time frame: 5 years inclusive of parent study

  2. Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in BCVA based on ETDRS score in the study eye at assessed timepoints

    To evaluate the persistence of effect of ABBV-RGX-314 on best corrected visual acuity (BCVA)

    Time frame: 5 years inclusive of parent study

  3. Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in CRT as measured by SD-OCT in the study eye at assessed timepoints

    To evaluate the persistence of effect of ABBV-RGX-314 on central retinal thickness (CRT), as measured by spectral domain-optical coherence tomography (SD-OCT)

    Time frame: 5 years inclusive of parent study

  4. Mean number of supplemental anti-VEGF injections through years 2, 3, 4 and 5

    To assess the need for supplemental anti-vascular endothelial growth factor (anti-VEGF) therapy

    Time frame: 5 years inclusive of parent study

  5. Mean number of supplemental anti-VEGF injections in years 2, 3, 4, and 5

    To assess the need for supplemental anti-vascular endothelial growth factor (anti-VEGF) therapy

    Time frame: 5 years inclusive of parent study

  6. Mean supplemental anti-VEGF injection annualized rate through years 2, 3, 4, and 5

    To assess the need for supplemental anti-vascular endothelial growth factor (anti-VEGF) therapy

    Time frame: 5 years inclusive of parent study

  7. Mean supplemental anti-VEGF injection annualized rate in years 2, 3, 4, and 5

    To assess the need for supplemental anti-vascular endothelial growth factor (anti-VEGF) therapy

    Time frame: 5 years inclusive of parent study

  8. Mean number of retina specialist visits attended for nAMD through years 2, 3, 4, and 5

    To assess the need of clinic visits for management of nAMD

    Time frame: 5 years inclusive of parent study

  9. Mean number of retina specialist visits attended for nAMD in years 2, 3, 4, and 5

    To assess the need of clinic visits for management of nAMD

    Time frame: 5 years inclusive of parent study

07

Study locations

16 sites
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Jul 2031, 115 months after the start.

Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's planned 115 months is above that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2022
First posted
Jan 27, 2022
StartActual
Dec 20, 2021
Primary completionEst.
Jul 2031
CompletionEst.
Jul 2031
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05210803
Lead sponsor
AbbVie
Collaborators
REGENXBIO Inc.
Responsible party
Sponsor
First posted
Jan 27, 2022
Start date
Dec 20, 2021
Primary completion
Jul 2031 (estimated)
Completion
Jul 2031 (estimated)
Last update
Aug 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion